Recent years have brought a significant amount of new results in the field of atherosclerosis.
A better understanding of the role of different lipoprotein particles in the formation of …

The cardiovascular science community has pursued the quest to identify vulnerable
atherosclerotic plaque in patients for decades, hoping to prevent acute coronary events …

Background The proprotein convertase subtilisin kexin type-9 inhibitor evolocumab
produced coronary atheroma regression in statin-treated patients. Objectives The purpose of …

Background In patients with coronary artery disease who are being evaluated for
percutaneous coronary intervention (PCI), procedures can be guided by fractional flow …

Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …

Importance Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive
statin therapy reduces progression of coronary atherosclerosis in proportion to achieved …

Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …

Background: Despite standard statin therapy, a majority of patients retain a high “residual
risk” of cardiovascular events. Objectives: The aim of this study was to evaluate the effects of …

Background Statins reduce adverse cardiovascular outcomes and slow the progression of
coronary atherosclerosis in proportion to their ability to reduce low-density lipoprotein (LDL) …

Background There is a residual risk of coronary heart disease (CHD) despite intensive statin
therapy for secondary prevention. The aim of this study was to investigate whether coronary …